Tern Plc expects final results on 31 May 2023 Q&A Session to follow

Tern plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (“IoT”) technology businesses, has announced that it expects to publish its final results for the year ended 31 December 2022 on Wednesday 31 May 2023.

Investor Q&A Session

The Company’s Chairman, Ian Ritchie, and CEO, Al Sisto, will conduct a live question and answer session for investors on 12 June 2023 at 5:30 pm BST.  The session is open to all existing and potential shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_YYea-W2XQgeqJ7WUDPHnuQ

Participants will have the opportunity to submit questions for Tern Plc during the session, but questions are welcomed in advance and may be submitted to: [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern notes automotive momentum at Device Authority

Tern Plc notes that Device Authority, in which it holds a 25.3% stake, has announced further progress in the automotive sector, securing a new OEM customer and expanding an existing Tier 1 deployment.

Key management emerges as a delivery risk in automotive software

Key management is becoming a delivery-critical constraint in software-defined vehicles, influencing risk, compliance and programme scalability.

Pharma teams gain early insight into message effectiveness

Talking Medicines gives pharma teams early insight into which messages resonate with healthcare professionals.

Talking Medicines joins 2026 UK AI Index

Talking Medicines joins the UK AI Index 2026, confirming its growing role in data-driven healthcare strategy.

AI in Healthcare 2025

In 2025, AI began reshaping healthcare delivery and marketing with practical applications, signalling a maturing investment landscape.

Talking Medicines targets messaging risk in pharma brand strategy

Talking Medicines reduces messaging risk for pharma brands by measuring real-time HCP response.

Search

Search